Loncar Investments Launches Cancer Immunotherapy Index

Loncar Investments Launches Cancer Immunotherapy Index

LCINDX tracks unique Biotechnology sector similar to sector indices in Technology

Lenexa, KS -- April 7, 2015 -- Loncar Investments, LLC today announced the Loncar Cancer Immunotherapy Index (LCINDX), the first professional index to track the transformational immunotherapy field within the biotechnology space.  The LCINDX index seeks to track the performance of a basket of companies that develop therapies to treat cancer by harnessing the body's own immune system.  The index will provide a metric to follow its progress as researchers advance new technologies for the benefit of patients who fight cancer disease.  LCINDX is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in immunotherapy.

"Cancer immunotherapy is driving innovations that have the potential to transform the therapeutic treatment of cancer," remarked Brad Loncar, CEO of Loncar Investments.  "The goal of the Cancer Immunotherapy index is to give investors a better understanding of the immunotherapy sector by highlighting major companies involved and providing a metric to track their progress.  We hope that highlighting immunotherapy in this fashion will lead to more awareness within the investment community, more investment in the field, and more progress for patients who battle cancer disease."

Why immunotherapy:  Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated.  While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease.  Some immunotherapies have already exhibited uncommon results in clinical trials including partial and complete responses in late stage cancer patients.

Professional sector index:  LCINDX is a professional equal-weighted index of 25 top immunotherapy companies rebalanced and reconstituted on a semi-annual basis.  Price and return data are independently calculated on a daily basis by Indxx, LLC.   Quotes for the symbol "LCINDX" can be found on the Bloomberg Professional service, www.LoncarIndex.com, and other financial data providers.   Principal constituents within the index include:  Bristol-Myers Squibb, Merck & Co., Juno Therapeutics, Kite Pharma, Cellectis and Bellicum Pharmaceuticals.  LCINDX is a sector index similar to Technology sector indices (Internet, Cyber Security, Cloud Computing, etc.).  Sector indices allow investors to track interest areas more precisely than broad indices.

Additional info can be found at the index's dedicated website, www.LoncarIndex.com.

Index provider:  Loncar Investments, LLC, the provider of the LCINDX index, is committed to making the biotechnology space more approachable to a wider range of investors.  The company is principally owned by biotech investor Brad Loncar.  Mr. Loncar manages a biotech-focused family portfolio from his Lenexa, Kansas office.  He is an independent investor and has no direct business relationship with any biotechnology companies, important factors in the company's ability to manage an unbiased index.  Mr. Loncar can be followed on Twitter at @bradloncar and his commentary is available at www.loncarblog.com.

Contact:

Brad Loncar

Phone: 913-871-5007

Email: [email protected]
 

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.